Last reviewed · How we verify
Sodium Thiosulfate (SODIUM THIOSULFATE)
Sodium nitrite forms methemoglobin to bind cyanide, while sodium thiosulfate donates sulfur for cyanide conversion to thiocyanate.
Sodium thiosulfate is a small molecule drug originally developed by the US Army, which remains its current owner. It is FDA-approved for reducing the risk of ototoxicity associated with cisplatin and treating the toxic effects of cyanide. Despite being off-patent, there are no generic manufacturers. As a result, its commercial status is uncertain. Key safety considerations include its potential effects on kidney function and electrolyte balance.
At a glance
| Generic name | SODIUM THIOSULFATE |
|---|---|
| Sponsor | Us Army |
| Drug class | sodium thiosulfate |
| Target | cytochrome a3, rhodanese |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1992 |
Mechanism of action
Sodium nitrite reacts with hemoglobin to form methemoglobin, which binds cyanide, preventing it from inhibiting cytochrome a3 and restoring aerobic metabolism. Sodium thiosulfate enhances the body's natural process of converting cyanide to less toxic thiocyanate, which is then excreted.
Approved indications
- Reduce the risk of ototoxicity associated with cisplatin
- Toxic effect of cyanide
Common side effects
- Hypotension
- Headache
- Disorientation
Key clinical trials
- Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies (PHASE1)
- Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI) (PHASE3)
- A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss (PHASE3)
- Quantification of Calcinosis Cutis Disease Burden Using Computed Tomography Images
- Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS) (PHASE1,PHASE2)
- Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors (PHASE1)
- Transtympanic STS Against Cisplatin-induced SNHL: the SOUND Trial (PHASE3)
- Comparing the Effect of Different Intracanal Dressing on Failed Root Canal Treated Cases on Periapical Healing (PHASE2)
Patents
| Patent | Expiry | Type |
|---|---|---|
| 9345724 | 2030-07-07 | Compound |
| 8496973 | 2031-03-29 | Compound |
| 11998604 | 2039-07-01 | Method of Use |
| 11992530 | 2039-07-01 | Method of Use |
| 11964018 | 2039-07-01 | Method of Use |
| 10479686 | 2030-07-07 | Formulation |
| 11753301 | 2030-02-10 | Compound |
| 10596190 | 2038-01-05 | Method of Use |
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sodium Thiosulfate CI brief — competitive landscape report
- Sodium Thiosulfate updates RSS · CI watch RSS
- Us Army portfolio CI